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baseline cholesterol levels and relevant co-morbidity. RESULTS:
A total of 2341 patients were identiﬁed, of these 644 were initi-
ated on rosuvastatin (93% on 10 mg), 606 on atorvastatin (53%
on 10 mg, 39% on 20 mg), 613 on simvastatin (70% on 20 mg),
440 on pravastatin (79% on 40 mg) and 38 on ﬂuvastatin (79%
on 80 mg). Secondary prevention accounted for approximately
30% of patients. Average percent LDL-C reductions were 48.0
(CI95%: 46.6–49.5), 41.7 (CI95%: 39.9–43.4), 38.7 (CI95%:
37.3–40.0), 32.0 (CI95%: 30.1–33.9), and 29.7 (CI95%:
23.9–35.5) for rosuvastatin, atorvastatin, simvastatin, pravas-
tatin and ﬂuvastatin respectively. The proportion of patients
attaining cholesterol goals was 75% for rosuvastatin, 68% for
atorvastatin, 56% for simvastatin, 42% for pravastatin, and
34% for ﬂuvastatin. After adjustment for risk factors the use of
rosuvastatin was signiﬁcantly associated with both greater LDL-
C reduction (mean differences 5.4% to 18.3%, all p < 0.001),
and with increased goal attainment (odds ratios 0.60 to 0.11, all
p < 0.001) compared to users of other statins. CONCLUSION:
We found evidence that in a real life setting, both percentage
LDL-C reduction and the proportion of patients attaining 2003
European cholesterol goals is signiﬁcantly greater among users
of rosuvastatin compared to other statins. Results are consistent
with those reported in clinical trials.
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OBJECTIVE: To examine Medicare resource utilization and
costs among patients with congestive heart failure (CHF) over
the course of one year after an initial CHF hospital discharge.
METHODS: Statistical analyses were conducted on Medicare
Standard Analytic Files. A cohort of patients with an initial inpa-
tient hospitalization for CHF between January 1, 1999 and
December 31, 2000 were identiﬁed and followed for a period of
one year. Outcomes assessed included the number of readmis-
sions (CHF-related and all-cause) and emergency department
(ED) visits; the mean time to each readmission/visit; mortality
following discharge; number and timing of physician ofﬁce visits;
and total charges. Multivariate regression analyses were con-
ducted to assess the likelihood of hospital readmission, likeli-
hood of death, and total charges adjusting for patient
characteristics and compliance with routine care. RESULTS: A
cohort of 690,800 patients (weighted) was identiﬁed. Within one
year of their initial hospitalization, approximately 20 percent of
patients (136,460; 19.75%) were readmitted for CHF and over
one-half (350,660; 50.76%) were readmitted for all causes. The
time-to-event analysis revealed that increasing the time to ﬁrst
readmission decreases the overall number of readmissions and
associated costs. Over 50% of patients visited the ED within 3
months of hospital discharge. The one-year mortality rate was
31.4%. The patient population that was readmitted within 30
days of initial hospital discharge accumulated the highest total
charges over the course of the year (mean = $66,639). In the mul-
tivariate model, the main cost drivers were the number of hos-
pital readmissions and death anytime within the year (potentially
due to high end-of-life costs). CONCLUSIONS: The large pro-
portion of hospital readmissions and ED visits occurring shortly
after discharge suggests that many patients are not sufﬁciently
managed once outside the hospital. Increased compliance with
physician visits could help decrease the overall number of both
CHF-related and all-cause readmissions.
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All cause mortality in the placebo group of ASCOT-LLA (Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering arm) was
1.28%. ASCOT-LLA included hypertensive patients (HP) in
primary prevention, with TC ≥ 6.5 mmol/L, not treated with
statins and with at least 3 cardiovascular risk factors (CVRF). A
lower CV morbimortality with atorvastatin ten mg vs placebo
was demonstrated. OBJECTIVES: Evaluate the real world mor-
tality of HP as deﬁned in ASCOT-LLA in a Mediterranean pop-
ulation of HP not treated with statins. METHODS: Patients
from seven primary care centres with a diagnosis of HT (CIAP
= K86-K87) were included in a multicentric registry of one year
follow-up (2004–2005) (n = 6309 patients). Main analysed vari-
ables were: basal age-sex, diabetes mellitus, stroke, smoking,
TC/HDL-ratio and all cause mortality (2004). RESULTS: Of the
6309 patients, 2528 (40%) had a history of CHD and/or heart
failure (HF) and/or TC > 6.5 mmol/L and/or statin treatment and
were excluded from the analysis. In the remaining 3781, CVFR
≥ 3 was conﬁrmed in 831. The annual mortality of these patients
was 2.89%, greater than ASCOT-LLA placebo group. In the
group of 3781 patients with no history of cardiac disease nor
TC > 6.5 mmol/L and without statin treatment, those with CVRF
≥ 3 had a higher mortality (2.89%) vs CVRF < 3 (1.86%)
(Fisher: p = 0.0497; χ2 : p = 0.0795). A signiﬁcant relationship
was demonstrated among CVRF number and mortality: 0
CVRF-0% mortality; 1 CVRF:1.4% mortality; 2 CVRF:2.7%
mortality; 3 CVRF:2.0% mortality; 4 CVRF:4.8% mortality; ≥5
CVRF:5.9% mortality (Mantel-Haenzel test: p = 0.003). CON-
CLUSIONS: Our data suggest that real world mortality of
ASCOT-like hypertensives in a Mediterranean population is
greater than the mortality found in the ASCOT (2.89% vs.
1.29%). A signiﬁcant relationship was demonstrated among
CVRF and mortality. Our data also suggest that the presence of
CVRF ≥ 3 indicates a high mortality risk.
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OBJECTIVE: Rimonabant, the ﬁrst selective CB-1 receptor
blocker, has proven effective in improving cardiometabolic risk
factors and reducing weight in overweight and obese individu-
als. This study evaluated its cost-effectiveness in patients with a
BMI > 27 kg/m2 in the UK. METHODS: A discrete event simu-
lation was created to take into account multiple time-dependent
risk factors—it predicts changes in anthropomorphic and phys-
iologic parameters based on analysis of pooled RIO trials data,
while simultaneously predicting onset of diabetes, cardiovascu-
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lar events and diabetic complications. After 100,000 individuals
are assigned baseline characteristics by sampling UK data, their
baseline risks are predicted and they enter a main module where
these are applied. Periodic updating takes place at doctors’ visits
and other events, such as premature treatment discontinuation
and complications. Resource use, costs and utilities were
obtained from UK databases. All outcomes are discounted at
3.5%/year. RESULTS: After one year treatment, patients on
rimonabant plus diet and exercise lose more than three times the
weight and show greater improvements in other cardiometabolic
risk factors than patients on diet and exercise alone. With diet
and exercise, 633 cardiovascular and 411 microvascular events
are predicted to occur per 1000 patients, over 60 years. Lifetime
costs average ≤5692/patient. One year of rimonabant reduces
cardiovascular and microvascular events by 18 and 10, respec-
tively, with a corresponding reduction in complication costs. Dis-
counted life expectancy increases by 40.2 years, and QALYs by
113.8. Extending treatment to 5 years increases life years and
QALYs gained by a further 38 and 48%, respectively. Extensive
sensitivity analyses, including varying the cost of treatment with
rimonabant, indicate that rimonabant is cost-effective over a
wide range of inputs. CONCLUSIONS: Rimonabant for the
treatment of overweight or obese patients with or without
comorbidities in the UK should be associated with acceptable
cost-effectiveness ratios under a wide range of assumptions.
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OBJECTIVES: The goal of this paper is to test the leader-
follower model in the Argentinean pharmaceutical markets
where patent protection does not apply allowing immediate
entry. METHODS: It was used a leader-follower model where
followers take leader prices to decide their own ones and the
leader strategically incorporates followers’ behavior in its deci-
sion. Two different groups of followers are studied separating
the main three from the rest of the market competitors. The data
used in this study is based in information published by Pharma-
ceutical Markets Argentina (PMA) complemented with indica-
tors of needs and chronicity, obtained through interviews with
physicians and pharmacologists, as well as the list of chemical
entities used in the production of each product, and the nation-
ality of manufactures. RESULTS: From the group of 88 thera-
peutic classes selected, 56 classes kept the same leader during the
period 1988–1995, although just in nine of those cases the ﬁrst
entrant remains as market leader. The cases where market leader
remains the same during the sample period but they were not
necessarily the ﬁrst entrants are deﬁned as loose leadership
markets, while cases of strict leadership are those where ﬁrst
entrants remained as market leaders during the sample period.
CONCLUSIONS: The leader-follower hypothesis is checked and
supported by the data, mirroring the results obtained under a
patent regime. In addition, the lack of patents also raises the
question of difference in behavior among followers. Therefore,
two differentiated groups of followers are studied separating the
main three from the rest of the market competitors.
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Stroke is the leading cause of long term disability worldwide and
a frequent cause of hospital admissions. Considering the popu-
lation aging, stroke is a growing health problem, and is increas-
ingly more costly to manage. Financial burden is caused by the
outcomes of acute stroke and its impact on a variety of health
care resources. OBJECTIVES: To provide referential of health
care resources and direct medical costs of post-acute manage-
ment of stroke per handicap levels within the new French
National Health System context. METHODS: Information pro-
vided by ECIC study on post-acute care delivered to 434 con-
secutive patients with stroke was considered to update data on
the cost of stroke in France. Data on handicap levels assessed 10
days after stroke onset (Rankin scale), medication, rehabilita-
tion, nursing care and ambulatory costs were obtained over 12
and 18 months after the initial acute hospital discharge. With a
NHS perspective, only direct medical costs were considered.
RESULTS: The mean direct medical cost of stroke in France, all
handicap levels considered, is estimated at €15,644 and €17,699
over the ﬁrst 12 and 18 month-periods respectively. At 18
months this cost increases from €8624.5 for patient with Rankin
1 to €39,010.5 for patients with Rankin 5. For patients with
lower handicap (Rankin 1–3) hospitalisation for the acute 
management of stroke is the main driver of costs, whereas for
patients with higher Rankin rehabilitation accounts for 70% of
the total direct medical costs. CONCLUSION: Costs increase by
ﬁve fold between the lowest and the highest handicap level.
Whatever the Rankin considered, costs incurred during the ﬁrst
year represent almost 90% of cost at 18 months. New thera-
peutic advances reducing post-stroke consequences could have a
major impact on health care expenditures.
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OBJECTIVES: While breast cancer has a high incidence world-
wide, there is limited data on treatment costs to help decision-
makers establish the cost-effectiveness of new treatments. This
study’s objective was to determine treatment costs of BC stages
for postmenopausal BC patients in Hungary. METHODS: BC-
speciﬁc resource use items were collected retrospectively on three
cohorts: early breast cancer (EBC), local regional recurrence
(LRR) and metastatic breast cancer (MBC) patients. Data was
obtained from National Health Insurance Fund claims databases
on inpatients, outpatients and pharmaceuticals. Cohorts were
determined using ICD, WHO, ATC, TNM and procedure codes.
Age > 55 served as proxy for postmenopausal status. The ﬁrst
100 relevant patients at each stage entering the Oncology Report
database in 2003 were included and followed for 1 year. Average
annual patient costs with 95% conﬁdence intervals (95%CI)
were established using Hungarian national fee schedules and
reported in euros. RESULTS: The ﬁnal cohort included 87
patients with incident EBC, 79 patients with LRR, and 99
patients receiving active or palliative care for MBC. The fre-
quency of diagnostic and surgical procedures, consultant visits
